John L Johnson
Overview
Explore the profile of John L Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
3259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chang V, Imperial M, Phillips P, Velasquez G, Nahid P, Vernon A, et al.
Nat Commun
. 2024 Oct;
15(1):9400.
PMID: 39477924
The Phase 3 randomized controlled trial, TBTC Study 31/ACTG A5349 (NCT02410772) demonstrated that a 4-month rifapentine-moxifloxacin regimen for drug-susceptible pulmonary tuberculosis was safe and effective. The primary efficacy outcome was...
2.
Becken B, Dousa K, Johnson J, Holland S, Bonomo R
Antimicrob Agents Chemother
. 2024 May;
68(7):e0031924.
PMID: 38757973
Treatment of infection presents significant challenges, exacerbated by the emergence of macrolide-resistant strains that necessitate the use of multiple antimicrobials in combination and carry the potential for significant toxic effects....
3.
Mutavhatsindi H, Manyelo C, Snyders C, van Rensburg I, Kidd M, Stanley K, et al.
J Infect
. 2024 May;
89(1):106173.
PMID: 38734311
Background: There is a need for new tools for monitoring of the response to TB treatment. Such tools may allow for tailored treatment regimens, and stratify patients initiating TB treatment...
4.
Johnson J, Sargsyan D, Neiman E, Hart A, Stojmirovic A, Kosoy R, et al.
JCI Insight
. 2024 Feb;
9(3).
PMID: 38329124
The role of long noncoding RNAs (lncRNAs) in disease is incompletely understood, but their regulation of inflammation is increasingly appreciated. We addressed the extent of lncRNA involvement in inflammatory bowel...
5.
Kaawa-Mafigiri D, Nsereko M, Odie M, Johnson J
PLoS One
. 2023 Oct;
18(10):e0293174.
PMID: 37862303
This study sought to assess perceptions towards and reasons for participation in research bronchoscopy studies in a high TB burden urban setting. Additionally, the study aimed to identify areas of...
6.
Kurbatova E, Phillips P, Dorman S, Sizemore E, Bryant K, Purfield A, et al.
Am J Respir Crit Care Med
. 2023 Feb;
207(10):1376-1382.
PMID: 36790881
We developed a standardized method, possible poor treatment response (PPTR), to help ascertain efficacy endpoints in Study S31/A5349 (NCT02410772), an open-label trial comparing two 4-month rifapentine-based regimens with a standard...
7.
Vierbuchen T, Agarwal S, Johnson J, Galia L, Lei X, Stein K, et al.
Proc Natl Acad Sci U S A
. 2022 Dec;
120(1):e2213715120.
PMID: 36577072
The nuclear long non-coding RNA LUCAT1 has previously been identified as a negative feedback regulator of type I interferon and inflammatory cytokine expression in human myeloid cells. Here, we define...
8.
Looney A, Day J, Johnson J, Johnston P
J Am Acad Orthop Surg Glob Res Rev
. 2022 Nov;
6(11).
PMID: 36322637
Introduction: Both stemmed and stemless designs for total shoulder arthroplasty (TSA) have demonstrated efficacious outcomes for the surgical treatment of primary glenohumeral joint osteoarthritis. The purpose of this systematic review...
9.
Pettit A, Phillips P, Kurbatova E, Vernon A, Nahid P, Dawson R, et al.
Clin Infect Dis
. 2022 Aug;
76(3):e580-e589.
PMID: 36041016
Background: Tuberculosis (TB) Trials Consortium Study 31/AIDS Clinical Trials Group A5349, an international randomized open-label phase 3 noninferiority trial showed that a 4-month daily regimen substituting rifapentine for rifampin and...
10.
Alameh M, Tombacz I, Bettini E, Lederer K, Sittplangkoon C, Wilmore J, et al.
Immunity
. 2022 Jun;
55(6):1136-1138.
PMID: 35704995
No abstract available.